Results 181 to 190 of about 4,861,792 (337)

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with ...
Michael T. Eadon   +18 more
wiley   +1 more source

Angiotensin II Receptors in Bovine Adrenal Cortex

open access: hybrid, 1974
Hartmut Glossmann   +2 more
openalex   +1 more source

Estimation of Plasma Volume by Machine Learning to Improve the Interpretation of the Athlete Biological Passport

open access: yesDrug Testing and Analysis, EarlyView.
A new machine learning model for plasma volume (PV) estimation was applied within the ABP framework. PV estimation was applied through visual displays or corrected ABP thresholds. With a favorable assessment from ABP experts, these results support further application of this model in the presence of specific confounding factors.
Bastien Krumm   +6 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Response of cultured primary gingival and periodontal ligament cells to angiotensin II and IL1β challenges. [PDF]

open access: yesBraz Oral Res
Garbieri TF   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy